HUE042720T2 - Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén - Google Patents
Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révénInfo
- Publication number
- HUE042720T2 HUE042720T2 HUE12813295A HUE12813295A HUE042720T2 HU E042720 T2 HUE042720 T2 HU E042720T2 HU E12813295 A HUE12813295 A HU E12813295A HU E12813295 A HUE12813295 A HU E12813295A HU E042720 T2 HUE042720 T2 HU E042720T2
- Authority
- HU
- Hungary
- Prior art keywords
- preventing
- methods
- inhibiting binding
- treating certain
- certain disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570018P | 2011-12-13 | 2011-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE042720T2 true HUE042720T2 (hu) | 2019-07-29 |
Family
ID=47552959
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12813295A HUE042720T2 (hu) | 2011-12-13 | 2012-12-12 | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
| HUE18197286A HUE054342T2 (hu) | 2011-12-13 | 2012-12-12 | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18197286A HUE054342T2 (hu) | 2011-12-13 | 2012-12-12 | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére render IL-4 és/vagy IL-13 receptorához történõ kötõdésének gátlásával |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9572863B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2790719B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6163162B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN109432402B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012350660B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2858962C (cg-RX-API-DMAC7.html) |
| DK (2) | DK3453400T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2863410T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE042720T2 (cg-RX-API-DMAC7.html) |
| PL (2) | PL3453400T3 (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201604566QA (cg-RX-API-DMAC7.html) |
| TR (1) | TR201901826T4 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013087660A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986951B2 (en) * | 2010-06-08 | 2015-03-24 | Pieris Ag | Tear lipocalin in muteins binding IL-4 R alpha |
| TR201901826T4 (tr) * | 2011-12-13 | 2019-03-21 | Astrazeneca Ab | Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. |
| SG10201912019WA (en) * | 2014-05-22 | 2020-02-27 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| JP7108535B2 (ja) | 2015-07-15 | 2022-07-28 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ－３に特異的な新規タンパク質 |
| CN113372446A (zh) * | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
| KR20190104409A (ko) | 2017-01-18 | 2019-09-09 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3에 대하여 결합 친화성을 갖는 리포칼린 뮤테인 |
| AU2018254542B2 (en) * | 2017-04-21 | 2022-12-22 | Elanco Us Inc. | IL4/IL13 receptor molecule for veterinary use |
| CN111494625B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| SG11202109839YA (en) | 2019-03-29 | 2021-10-28 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| CA3127973A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
| CR20230265A (es) | 2020-12-18 | 2023-09-29 | Astrazeneca Ab | Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma |
| CN115414467B (zh) * | 2022-10-14 | 2023-06-06 | 中国人民解放军陆军军医大学第二附属医院 | 载脂蛋白d在制备治疗脑出血药物中的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE4425255A1 (de) | 1994-07-16 | 1996-01-18 | Asta Medica Ag | Formulierung zur inhalativen Applikation |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6446467B1 (en) | 1997-07-29 | 2002-09-10 | Physical Optics Corporation | Monolithic glass light shaping diffuser and method for its production |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| KR20010052622A (ko) | 1998-06-08 | 2001-06-25 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 만성 씨형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-알파 및 리바비린의 용도 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| DE10043509A1 (de) | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| AU2003233583A1 (en) * | 2002-05-24 | 2003-12-12 | Agennix Incorporated | Oral lactoferrin in the treatment of respiratory disorders |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| RU2389796C2 (ru) | 2003-08-29 | 2010-05-20 | Аэровэнс, Инк. | Модифицированный антагонист рецептора il-4 и предназначенный для его получения очищенный полинуклеотид |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US8598317B2 (en) | 2006-03-20 | 2013-12-03 | Technische Universitaet Muenchen | Muteins of tear lipocalin with affinity for the T-cell coreceptor CD4 |
| JP5608368B2 (ja) | 2006-08-01 | 2014-10-15 | ピエリス アーゲー | 涙リポカリンの突然変異タンパク質およびそれを得るための方法 |
| KR20100047866A (ko) * | 2007-07-11 | 2010-05-10 | 애로반스, 인코포레이티드 | 약제학적 폴리펩타이드 건조 분말 에어로졸 제형 및 이의 제조 방법 |
| US8986951B2 (en) | 2010-06-08 | 2015-03-24 | Pieris Ag | Tear lipocalin in muteins binding IL-4 R alpha |
| TR201901826T4 (tr) | 2011-12-13 | 2019-03-21 | Astrazeneca Ab | Il-4 ve/veya ıl-13'ün ilgili reseptörlerine bağlanmasını inhibe ederek belirli rahatsızlıkların önlenmesi ya da tedavi edilmesi için yöntemler. |
-
2012
- 2012-12-12 TR TR2019/01826T patent/TR201901826T4/tr unknown
- 2012-12-12 ES ES18197286T patent/ES2863410T3/es active Active
- 2012-12-12 EP EP12813295.8A patent/EP2790719B1/en active Active
- 2012-12-12 PL PL18197286T patent/PL3453400T3/pl unknown
- 2012-12-12 HU HUE12813295A patent/HUE042720T2/hu unknown
- 2012-12-12 CA CA2858962A patent/CA2858962C/en active Active
- 2012-12-12 PL PL12813295T patent/PL2790719T3/pl unknown
- 2012-12-12 ES ES12813295T patent/ES2710384T3/es active Active
- 2012-12-12 EP EP21152253.7A patent/EP3842058B1/en active Active
- 2012-12-12 WO PCT/EP2012/075146 patent/WO2013087660A1/en not_active Ceased
- 2012-12-12 SG SG10201604566QA patent/SG10201604566QA/en unknown
- 2012-12-12 CN CN201811146540.5A patent/CN109432402B/zh not_active Expired - Fee Related
- 2012-12-12 DK DK18197286.0T patent/DK3453400T3/da active
- 2012-12-12 EP EP18197286.0A patent/EP3453400B1/en active Active
- 2012-12-12 CN CN201280061754.7A patent/CN103998053B9/zh not_active Expired - Fee Related
- 2012-12-12 SG SG11201402992SA patent/SG11201402992SA/en unknown
- 2012-12-12 US US14/364,449 patent/US9572863B2/en not_active Expired - Fee Related
- 2012-12-12 HU HUE18197286A patent/HUE054342T2/hu unknown
- 2012-12-12 DK DK12813295.8T patent/DK2790719T3/en active
- 2012-12-12 AU AU2012350660A patent/AU2012350660B2/en not_active Ceased
- 2012-12-12 JP JP2014546471A patent/JP6163162B2/ja not_active Expired - Fee Related
-
2016
- 2016-12-02 US US15/367,680 patent/US10016483B2/en active Active
-
2017
- 2017-03-30 JP JP2017067615A patent/JP6725447B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-07 US US16/002,704 patent/US10398754B2/en active Active
-
2019
- 2019-03-28 JP JP2019062186A patent/JP6889201B2/ja not_active Expired - Fee Related
- 2019-07-16 US US16/513,636 patent/US10857202B2/en not_active Expired - Fee Related
-
2020
- 2020-05-27 JP JP2020092168A patent/JP2020164532A/ja active Pending
- 2020-11-05 US US17/090,571 patent/US11382951B2/en active Active
-
2022
- 2022-03-25 JP JP2022049676A patent/JP7441589B2/ja active Active
- 2022-06-14 US US17/839,635 patent/US20230021168A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311262B2 (en) | Methods for treating or preventing cholesterol-related disorders | |
| HUE042720T2 (hu) | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén | |
| IL274469A (en) | Compositions, uses and methods for the treatment of metabolic disorders and diseases | |
| IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
| ZA201606957B (en) | Biguanide compositions and methods of treating metabolic disorders | |
| ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
| IL229257A0 (en) | Preparations and methods for the treatment of diseases related to the retina of the eye | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| EP2675460A4 (en) | TREATMENT OF FAT TISSUE UNDER CHIN | |
| IL232710A0 (en) | l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders | |
| IL231151A0 (en) | Method and preparation for treating lice | |
| IL230433A0 (en) | Pain management methods | |
| IL232190A0 (en) | A method for treating inflammatory diseases by anti-m-csf antibodies | |
| EP2747768A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| IL231157A0 (en) | Preparations and methods for the treatment of neurodegenerative diseases | |
| IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
| AP2013007056A0 (en) | Methods and compositions for treating kidney disorders | |
| EP2919856A4 (en) | METHOD AND COMPOSITION FOR THE TREATMENT OF GASTRO-SOPHAGEAL DISORDERS | |
| ZA201309109B (en) | Methods of treating biomass | |
| IL227703A0 (en) | Converted Ometic Sulfur Compounds and Methods of Using Them | |
| GB201116335D0 (en) | A method of treating or preventing affective disorders | |
| GB201119458D0 (en) | Compositions for treatment of sleep disorders | |
| GB201101183D0 (en) | Treatment of neurodegenerative disorders | |
| GB201101773D0 (en) | Treatment of inflammatory disorders | |
| GB201118065D0 (en) | Treatment of movement disorders |